Cerdelga (eliglustat) — Medica

Initial criteria

• Patient is a cytochrome P450 2D6 extensive metabolizer, intermediate metabolizer, or poor metabolizer as detected by an approved test
• Diagnosis is established by ONE of the following: demonstration of deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts OR molecular genetic test documenting biallelic pathogenic glucocerebrosidase (GBA) gene variants
• Medication is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or a physician who specializes in the treatment of Gaucher disease or related disorders

Approval duration

1 year